Faculty Bios - Coming Soon top

Paul Bunn, Jr., MD
Distinguished Professor
James Dudley Chair in Lung Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Denver, CO

Paul Bunn, Jr., MD top

Dr. Paul Bunn is arguably one of the most important lung cancer medical oncologist researchers today and among the few experts during the past several decades.

In 1984, Dr. Bunn was recruited to the University of Colorado Health Sciences Center as a Professor of Medicine in Medical Oncology and Head of the Division of Medical Oncology. In 1986 Dr. Bunn became the Director of the University of Colorado Comprehensive Cancer Center.

Dr. Bunn has also been President of the American Society of Clinical Oncology the leading cancer organization of oncology professionals in the world. The network of the American Society of Clinical Oncology comprises nearly 40,000 oncology professionals, about one-third being from more than 100 countries outside of the USA. This organization is dedicated to providing the highest-quality resources in education, policy, clinical research, and in advancing care for patients with cancer. The results of clinical trials presented at its annual meeting are a benchmark of year-to-year progress in the fight against cancer. ASCO’s flagship publication, the Journal of Clinical Oncology (JCO), is an authoritative resource for cancer research findings.

Dr. Bunn has also been the President and Executive Director of the International Association for the Study of Lung Cancer (IASLC) where he held both positions for almost 20 years, until 2013. Under his leadership Dr. Bunn built the IASLC to become the world’s largest association of oncologists, pathologists and healthcare professionals in lung cancer.

Dr. Bunn has also been the President of the Association of American Cancer Institutes (AACI) and has served on the prestigious FDA Oncology Drug Advisory Committee (ODAC) as its chairman.

He is the Chair or Co-Chair of numerous ongoing educational symposia and scientific, clinical and translational research meetings in lung cancer, including the Annual Targeted Therapies for Lung Cancer Meeting now in its seventeenth year held annually in Santa Monica, CA, the Annual Personalized Therapies and Best Clinical Practices for Lung Cancer now in its 9th year, held each year in October in San Francisco, and many others.

Dr. Bunn’s research interests focus on novel therapies for lung cancer. He has published more than 300 articles in peer-reviewed journals, over 122 reviews and editorials, and 90 book chapters on lung cancer. Dr. Bunn’s studies have set standards for the treatment of lung cancer, have identified issues of natural history and have identified biomarkers of prognosis and therapy selection. Dr. Bunn is the principal investigator on numerous national and local therapeutic trials and is also the principal investigator for the SPORE grant in lung cancer that is designed to conduct translational research in lung cancer.

Stephen Madison
President and CEO
Oncology Learning Center, Inc., and the
BioMedical Learning Institute
Plano, TX

Stephen Madison top

Steve Madison has been involved with the science and business of oncology/hematology since 1983. He started his career in the field of oncology and hematology as an oncology pharmacist, employed as a pharmaceutical industry marketing executive of Bristol-Myers (BM) for the BM oncology products starting in 1983 as one of only two international marketing executives within BM. In 1983, there were only three cancer pharmaceutical companies in the USA: Bristol-Myers (BM), Mead Johnson and Adria Laboratories. Steve was fortunate to have started establishing working relationships with the academic (“KOL”) leaders in oncology and hematology at the beginning of the oncology business era, 36 years ago. And to this day in 2016, Steve has maintained his important KOL relationships beginning with his employment at Bristol-Myers, but also through his subsequent cancer education and medical advertising companies as described below.

In 1994 Steve left Bristol-Myers and founded and operated, SG Madison & Associates, a global medical/marketing communications and advertising company, which as agency of record, helped successfully launch gemcitabine, trastuzumab, rituximab, cetuximab, and several other oncology and HIV products; but primarily Steve and his medical/marketing company supported the oncology & HIV franchises of Bristol-Myers (eventually Bristol-Myers Squibb) in the US and Globally, plus the businesses of ImClone, Genentech, Lilly and several other companies not on a retainer basis.

In 1999 Steve founded the first of his two CME/CE accredited companies: the CBCE (Center for Biomedical Continuing Education) which he sold in 2001 along with his medical/marketing communications agency, SG Madison & Associates. During his tenure at his two CME/CE companies and SG Madison & Associates, Steve founded several major ongoing cancer education meetings and symposia, and at least two of which are still ongoing today, including the now 17th Annual Anti-Angiogenic Symposium held each year in La Jolla, CA, sponsored by MD Anderson Cancer Center and co-chaired by Dr. George Sledge and Lee Ellis, the now 17th Annual Targeted Therapies for Lung Cancer Meeting, held each year in Santa Monica, CA, sponsored by the IASLC co-chaired by Drs. Paul Bunn, Roy Herbst, Dave Johnson and Fred Hirsch.

In 2006 Steve founded the Oncology Learning Center, Inc., (also operated as the BioMedical Learning Institute) which conducts numerous live and Web-based oncology/hematology educational CME/CE activities, including annual satellite CME/CE symposia at the annual meetings of the American Society of Clinical Oncology, the American Society of Hematology, the San Antonio Breast Cancer Symposium, the Oncology Nursing Society and many other meetings and congresses, and including of its own, stand-alone educational events (of the BLMI) including the annual Symposium on Personalized Therapies and Best Clinical Practices for lung Cancer now in its 9th consecutive year, and its 1st Annual Symposium on Integrating Immune Therapy and Targeted Therapy into Standards of Care for Hematologic and Solid Malignancies to be held on September 10, 2016 in San Francisco.

In addition, Steve and the Oncology Learning Center have now resumed the highly successful Cancer Master Classes that were suspended in 2005, beginning with the October 19-21, 2016 Strategic Cancer Business Master Class and Other Master Classes will follow shortly. Please see: www.OncologyLearningCenter.com

Finally, Steve owns but does not (presently) operate several other cancer businesses of importance to pharmaceutical and diagnostic/laboratory companies, including his cancer consulting company, Steve Madison Cancer Consulting, as well as his oncology KOL development company: InsiderMD.com; his customized oncology training company: CPLS.com (Customized Pharmaceutical Learning Systems), and also his customized cancer market research company: Oncology Insights.com. The reason for Steve’s lack of involvement (for the present), is the 2009 legislation prohibiting his participation in both CME and non CME companies. It is anticipated that this will change in the very near future as Steve his other executives to operate his CME business, thus enabling Steve to operate freely inside his non-CME businesses: InsiderMD.com, CPLS.com (Customized Pharmaceutical Learning Systems), Steve Madison Consulting.com and Oncology Insights.com. Should anyone be interested in any of these business or their services please contact Steve.Madison@CPLS.com.

Daniel Petrylak, MD
Professor of Medicine, Medical Oncology and Urology
Professor & Co-Director
Signal Transduction Research Program
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT

Daniel Petrylak, MD top

As Professor of Medicine and Urology at Yale School of Medicine, Dr. Daniel P. Petrylak is a pioneer in the research and development of new drugs and treatments to fight prostate, bladder, kidney and testicular cancer. For patients fighting these types of cancers, Petrylak finds recent developments in the field of immunotherapy particularly promising. “Up until recently, bladder cancer had not seen any major advancement in more than 30 years,” he says. “Studies are ongoing, but interim results are exciting so far.”

At the Smilow Cancer Hospital, Dr. Petrylak’s position as a national leader on clinical trials for men with prostate and bladder cancer has opened up a world of treatment options for patients in New England. “We offer the latest investigational drugs for these conditions, while providing the highest level of care,” he says.

Dr. Petrylak received his MD from Case Western Reserve University School of Medicine and joined the Yale faculty in 2012. In addition to his role as professor, he is also the co-director of the Signal Transduction Research Program at Yale Cancer Center, which studies how cancer stem cells are regulated in the body and communicate with surrounding tissue. Roughly 40 physicians and scientists in the program work together to develop the best methods for matching patients with the appropriate cancer drugs.

One of Dr. Petrylak’s key goals is to continue to successfully translate basic research into clinical practice. “One of the most significant accomplishments in my career was moving docetaxel (an antineoplastic agent) therapy for the most advanced form of prostate cancer from phase I to III,” he says. “We ran a trial which supported its approval for the most advanced form of prostate cancer.”

Dr. Petrylak currently serves as either the principal investigator or co-principal investigator on seven Southwest Oncology Group (SWOG) clinical trials for genitourinary cancers. To date, he has authored more than 100 peer-reviewed articles on prostate and bladder cancer research.

Stanley Riddell, MD
Professor, School of Medicine
University of Washington
Seattle Cancer Care Alliance
Seattle, WA

Stanley Riddell, MDtop

Prof. Stanley R. Riddell, also known as Stan, MD, is Scientific Co-Founder of Juno Therapeutics Inc. Prof. Riddell is a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center and Professor of Oncology at the University of Washington School of Medicine. Dr. Riddell is a leader in developing therapies that harness the immune system to fight cancer and infectious diseases. His research led to patented technologies that rapidly expand the number of disease fighting T cells used in adoptive immunotherapy. He also isolated a rare subset of disease-fighting T cells that survive in patients for an extraordinary amount of time. He joined FHCRC Faculty in 1991 after training in medical oncology and immunology. Dr. Riddell was elected to the Association of American Physicians, an organization honoring those who have achieved excellence in biomedical science. He served as an Associate Professor of University of Washington School of Medicine, since 2000. Mr. Riddell serves as a Member of Scientific Advisory Board of Cellerant Therapeutics Inc. He serves as Member of Scientific Advisory Team of Cell Medica Limited. He is a Member of the American Association for the Advancement of Science, the American Society of Gene Therapy, and the American Society of Hematology. He is the recipient of ASCO Young Investigator Award and the Cancer Research Institute Partridge Foundation Investigator Award. In 2010, Dr. Riddell received the International Society for Biological Therapy of Cancer’s first Team Science Award for major contributions to research and the clinical translation of cancer immunotherapy. Mr. Riddell earned his M.D. at University of Manitoba and is a Board Certified Medical Oncologist.

Susan Slovin, MD, PhD
Attending Physician, Member
Genitourinary Oncology Service
Sidney Kimmel Center for Prostate and Urologic Cancers
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Susan Slovin, MD, PhD top

Clinical Expertise: Prostate Cancer; Clinical Immunology; Other Genitourinary Malignancies
Education: MD, Jefferson Medical College; PhD, Columbia University Graduate School of Arts and Sciences
Residencies: Mount Sinai Medical Center (New York)
Fellowships: Memorial Sloan Kettering Cancer Center
Board Certifications: Internal Medicine; Medical Oncology

Click here for a list of publications.

Clinical Trials Led by Susan F. Slovin

  • A Phase Ib Study of Enzalutamide plus Ribociclib in Men with Advanced Prostate Cancer
  • A Phase II Study of Abiraterone with or without Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate Cancer
  • A Study Comparing the Cardiovascular Safety of Degarelix versus Leuprolide in Men with Cardiovascular Disease Receiving Hormonal Therapy for Advanced Prostate Cancer
  • Adoptive Transfer of Autologous T Cells Targeted to Prostate-Specific Membrane Antigen for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Clinical Trials Co-Investigated by Susan F. Slovin
  • A Phase I Study of a Vaccine-Based Immunotherapy (PrCa VBIR) for Prostate Cancer

David Spigel, MD
Director, Lung Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, TN

David Spigel, MD top

Dr. Spigel joined Sarah Cannon in 2003 and as chief scientific officer, he oversees all scientific aspects of Sarah Cannon's clinical trial program, working with the research physician leaders to ensure the best new agents and studies are available to our patients. He serves as a primary contact for the Pharma and biotech partners as well as the strategic site physicians with whom Sarah Cannon conducts cancer research.

Dr. Spigel received his bachelor’s degree from Tulane University in New Orleans in 1992, and medical degree from The University of Tennessee in Memphis in 1996. After completing an internal medicine and chief residency at Indiana University Medical Center, he completed a fellowship in hematology and oncology at The Dana-Farber Cancer Institute in Boston. He is board certified in medical oncology. Additionally, he is an associate with Tennessee Oncology, PLLC.

Mario Sznol, MD
Professor of Medicine
Yale University School of Medicine
Co-Director, Yale SPORE in Skin Cancer
Yale Comprehensive Cancer Center
New Haven, CT

Mario Sznol, MD top

Dr. Mario Sznol, M.D., served as Vice President of Clinical Affairs at Vion Pharmaceuticals Inc. from September 1999 to October 15, 2004. From 1987 to 1999, Dr. Sznol worked for the National Cancer Institute, or NCI, an institute of the National Institutes of Health. He served as Head of the Biologics Evaluation Section, Investigational Drug Branch, Cancer Therapy Evaluation Program from 1994 to 1999. From March 1997 to October 1998, he served as an Acting Chief of NCI's Investigational Drug Branch, Cancer Therapy Evaluation Program. He serves as a Member of Scientific Advisory Board at Lion Biotechnologies, Inc. He has been a Member of Scientific Advisory Board at Intensity Therapeutics, Inc. since October 22, 2015. He serves as a Member of Scientific Advisors at Anaeropharma Science, Inc. He serves as a Member of Scientific Advisory Board at Symphogen A/S. He has been a Member of Scientific Advisory Board at Lycera Corp. since November 10, 2016. He served as a Director of Vion Pharmaceuticals Inc. since October 15, 2004. He is a Professor of Internal Medicine, Co-Director of the Melanoma Program and Co-Director of Yale SPORE in Skin Cancer at Yale University School of Medicine. He is an investigator in several clinical trials at the Yale Cancer Center, including those focusing on immunotherapy and novel agents. He spent the next twelve years in the Biologics Evaluation Section (BES), Investigational Drug Branch of the Cancer Therapy Evaluation Program at the National Cancer Institute (NCI). Dr. Sznol has an international reputation in cancer drug development with expertise in cancer immunotherapy and the treatment of patients with melanoma and renal cell carcinoma. He conducted his fellowship in Medical Oncology, Department of Neoplastic Diseases, at Mt. Sinai School of Medicine and his residency in Internal Medicine at Baylor College of Medicine in Houston. Dr. Sznol received his BA from Rice University and an MD from the Baylor College of Medicine and Yale University School Of Medicine. He trained in internal medicine.

Jeffrey Weber, MD, PhD
Deputy Director, Laura & Isaac Perlmutter Cancer Center
Co-Director, Melanoma Program
Head of Experimental Therapeutics
NYU Langone NCI Comprehensive Cancer Center
New York, NY

Jeffrey Weber, MD, PhD top

Dr. Weber earned his Ph.D. in molecular cell biology from Rockefeller University (New York) in 1979 and received his M.D. from New York University in 1980. He completed his internship and residency in Medicine at the University of California, San Diego, and his fellowship in Medical Oncology at the National Cancer Institute in Bethesda, MD.

His experience includes clinical, research and teaching positions at the University of California, Irvine, and the University of Southern California where he was Chief of Medical Oncology and Associate Director for Clinical Research at the USC/Norris Comprehensive Cancer Center. Coming to Moffitt in 2007, Dr. Weber is a Senior Member, Director of the Donald A. Adam Comprehensive Melanoma Research Center, and Professor in the Department of Oncologic Sciences.

A specialist in cancer immunotherapy, Dr. Weber is principal investigator (PI) on several ongoing studies funded by the National Cancer Institute (NCI), including trials in clinical drug development, vaccines, and studies on autoimmunity and melanoma. He has been continuously NCI R01 funded for the last 16 years. Dr. Weber is also the Principal Investigator and Director of the Moffitt Skin Cancer SPORE (P50) NCI grant, a collaborative, multi-project translational research program. Dr. Weber has published more than 100 articles in the top peer-reviewed journals in his field including New England Journal of Medicine, Clinical Cancer Research, Journal of Clinical Oncology and Nature Medicine. Dr. Weber sat on the National Cancer Institute’s Clinical Oncology Study section as well as the boards of the Melanoma Research Foundation and the Melanoma Therapeutics Foundation, and served as a chair of the Veterans Administration’s clinical oncology study section. He currently sits on the scientific advisory boards of four cancer-related biotechnology companies.

Dr. Weber’s research interests are in the field of immunotherapy for cancer. As a translational clinical investigator, Dr. Weber has performed a variety of vaccine trials, protocols involving adoptive cell therapy, and novel immunotherapy trials in melanoma patients. His specific laboratory interests are in the monitoring and characterization of T cell responses in patients with cancer, and the establishment of in vitro models to facilitate the understanding of how immune modulation via abrogating and activating antibodies amplifies adaptive immunity in patients. Clinically, he has held 10 investigator-initiated IND over the last decade, and has pursued cutting edge trials recently using gene modified dendritic cells, intranodal injection of plasmid-peptide priming and boosting and novel antibodies like CTLA-4 and PD-1 abrogating antibodies. He has been a pioneer in the clinical advancement of antibodies that induce autoimmunity as a surrogate for clinical benefit in cancer, and the management of the autoimmune side effects.

Jared Weiss, MD
Assistant Professor
Division of Hematology and Oncology
School of Medicine
Clinical Research
Thoracic Oncology Program
University of North Carolina
Chapel Hill, NC

Jared Weiss, MD top

Clinically, Dr. Weiss is focused on treating patients with lung cancer and head and neck cancers. Dr. Weiss’ research is focused on clinical trials in lung cancer and head/neck cancer. Dr. Weiss serves as section chief of thoracic and head/neck oncology and research POD leader for thoracic oncology. Dr. Weiss serves as associate director for finance of the Clinical Protocol Office. He also serves as the vice president of cancergrace.org, a global resource with the goal of increasing patient education and family information on cancer and is an advocate and board member of the Lung Cancer Initiative of North Carolina.

Dr. Jared Weiss is a medical oncologist in Chapel Hill, North Carolina. He received his medical degree from Yale University School of Medicine and has been in practice between 11-20 years.

H. Jack West, MD
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
President and CEO
Global Resource for Advancing Cancer Education
Seattle, WA

H. Jack West, MD top

Dr. West received an MPhil in Experimental Biology from Cambridge University on a Fulbright Scholarship and a medical degree (magna cum laude) from Harvard Medical School, where Dr. West also conducted research as a Howard Hughes Medical Student Fellow. His postdoctoral training included an internship and residency in internal medicine at the Harvard-affiliated Brigham and Women’s Hospital Boston, MA, followed by a fellowship in medical oncology at the Fred Hutchinson Cancer Research Center/ University of Washington in Seattle, WA. He joined Swedish Cancer Institute in late 2002 as a medical oncologist and lung cancer specialist. He also serves as Medical Director of the Thoracic Oncology Program and has a significant clinical interest as well in genitourinary oncology.

Dr. West has published numerous articles in peer-reviewed literature and has authored several book chapters. He also now serves as the Web Editor of JAMA Oncology and is on the editorial boards of Journal of Clinical Oncology, Journal of Medicine, Clinical Lung Cancer, and Journal of Thoracic Disease, in addition to serving as an author of multiple lung cancer-related sections of Up-To-Date and as a reviewer for more than a dozen professional journals. Dr. West leads a wide range of clinical trials and has been actively involved with the SWOG Lung Cancer Committee as a Study Coordinator/Principal Investigator.

Dr. West founded and continues to serve as President of the nonprofit organization Global Resource for Advancing Cancer Education (GRACE), a source of timely, free information for patients and caregivers dealing with cancer that currently receives over 50 thousand visits per month from over 100 countries around the world.

Dr. West is also working to develop telemedicine-based practice patterns to broaden the range of treatment options for cancer patients and serves as the Chair of the Outreach/Education/Telemedicine Working Group for the Cancer Clinical Provider Group as part of the Providence/Swedish Hospital Network. He is also a regular session chair on numerous annual lung cancer an immune and targeted therapy CME symposia such as the Annual Personalized Therapies and Best Clinical Practices Symposia each year in October in San Francisco. He is often a co-chair of satellite educational symposia on lung cancer at the annual meeting of the American Society of Clinical Oncology in Chicago in May and June.

© 2018 Oncology Learning Center, Inc.